Last reviewed · How we verify
NCT04138420
Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab
trial testing Bevacizumab Injection in Exudative Age-related Macular Degeneration in 38 participants. Completed in 30 October 2017.
25 October 2017
Quick facts
| Lead sponsor | Federico II University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 38 |
| Start date | 25 January 2017 |
| Primary completion | 25 October 2017 |
| Estimated completion | 30 October 2017 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Bevacizumab Injection — full drug profile →
Conditions studied
- Exudative Age-related Macular Degeneration — all drugs for Exudative Age-related Macular Degeneration →
Sponsor
Federico II University
Who can join
Adults 50 to 80, any sex, with Exudative Age-related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the retinal and vascular features in patients with macular degeneration under the effects of Bevacizumab intravitreal injections using optical coherence tomography and optical coherence tomography angiography.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04138420
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bevacizumab Injection
Trials testing the same drug.
- NCT07111546 — A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)] · Phase 2 · recruiting
- NCT07089719 — Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study) · Phase 2 · not yet recruiting
- NCT06783647 — A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] · Phase 2 · recruiting
- NCT06703177 — A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT03698162 — Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases · NA · terminated
Other Federico II University trials
Trials by the same sponsor.
- NCT07437690 — Fall Prevention in Older Adults in an Italian Cohort · not yet recruiting
- NCT07282132 — Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter · not yet recruiting
- NCT07280286 — Incidence of Intrauterine Adhesions After Myomectomy With Intrauterine Anti-Adhesion Gel · NA · not yet recruiting
- NCT07374861 — Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy · recruiting
- NCT07314684 — GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04138420 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Federico II University
- Last refreshed: 24 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04138420.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing